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From the time when they were first described in the 1970s by the group of John-
stone and Stahl, exosomes are a target of constant research. Exosomes belong to
the family of nanovesicles which are of great interest for their many functions and
potential for diagnosis and therapy in multiples diseases. Exosomes originate from
the intraluminal vesicles of late endosomal compartments named multivesicular bodies
and the fusion of these late endosomes with the cell membrane result in the release
of the vesicles into the extracellular compartment. Moreover, their generation can be
induced by many factors including extracellular stimuli, such as microbial attack and
other stress conditions. The primary role attributed to exosomes was the removal of
unnecessary proteins from the cells. Now, several studies have demonstrated that
exosomes are involved in cell–cell communication, even though their biological function is
not completely clear. The participation of exosomes in cancer is the field of microvesicle
research that has expanded more over the last years. Evidence proving that exosomes
derived from tumor-pulsed dendritic cells, neoplastic cells, and malignant effusions
are able to present antigens to T-cells, has led to numerous studies using them as
cell-free cancer vaccines. Because exosomes derive from all cell types, they contain
proteins, lipids, and micro RNA capable of regulating a variety of target genes. Much
research is being conducted, which focuses on the employment of these vesicles
as biomarkers in the diagnosis of cancer in addition to innovative biomarkers for
diagnosis, prognosis, and management of cardiovascular diseases. Interesting find-
ings indicating the role of exosomes in the pathogenesis of several diseases have
encouraged researchers to consider their therapeutic potential not only in oncology
but also in the treatment of autoimmune syndromes and neurodegenerative disorders
such as Alzheimer’s and Parkinson’s disease, in addition to infectious diseases such
as tuberculosis, diphtheria, and toxoplasmosis as well as infections caused by prions
or viruses such as HIV. The aim of this review is to disclose the emerging roles of
exosomes in normal and pathological conditions and to discuss their potential therapeutic
applications.
Keywords: exosomes, therapeutics, cancer, neurodegenerative disorders, infectious disease therapy, biomarkers,
pharmacological
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In recent years, the study of extracellular vesicles (EVs) has
mainly focused in a type of vesicles secreted into the extracellular
compartment that were termed exosomes by Johnstone, who iso-
lated them from sheep reticulocytes and described their endocytic
origin (1). Later, other authors have described this type of vesicles
and their secretory pathway. These findings have been extensively
described in many comprehensive reviews (2–7).
The interest in EV and, in particular, in exosomes is reflected
in many reports published earlier and the constitution of the
International Society for Extracellular Vesicles in 2011 to discuss
important findings in the field and a database named Exocarta
(http://www.exocarta.org), created in 2009 as a free web-based
resource to compile proteins and RNA identified in exosomes (8).
Extracellular vesicles are constitutively released frommany cell
types including neurons, tumor and immune cells, among others.
They can also be found in different body fluids such as serum,
breast milk, saliva (9), cerebrospinal fluid (10), semen (11), and
urine (12).
Eukaryotic cells release vesicles into the extracellular
environment either by direct membrane budding (ectosomes
or microparticles: apoptotic vesicles, membrane particles and
exosome-like vesicles) or by fusion of internal multivesicular
compartments (exosomes) (7).
Exosomes are small particles of 30–100 nm with a membrane
that is rich in lipids such as sphingolipids, ceramide, and choles-
terol with a density between 1.15 and 1.19 g/ml (3).
Exosomes have an endocytic origin and their development
begins when early endosomes, loaded with ubiquitinilated pro-
teins, are recognized by the endosomal sorting complex required
for transport (ESCRT). This recognition allows the formation of
intraluminal vesicles which, in turn, give rise to themultivesicular
bodies (MVBs) containing proteins. This process continues with
the fusion of the MVBs with the plasma membrane releasing
their content to the extracellular space; the microvesicles released
are exosomes (3, 6, 13, 14). However, an independent ESCRT
pathway for exosomal biogenesis and release has recently been
described (6).
When exosomes are secreted outside the cells, they can follow
one of these three pathways: (1) they can be captured by neighbor-
ing cells (or by the same cells that have given rise to them); (2) they
can be internalized by cells that are within a certain distance; or
alternatively, (3) they can enter the systemic circulation and then
be taken up by different tissues (15).
Canonical exosomes can be described by the presence of
molecules which are specifically associated to them, regardless
of the cell type they derive from (16). For example, exosomes
express some typical cytosolic proteins such as tubulin and actin,
molecules involved in MVB biogenesis as TSG101 and Alix,
proteins that participate in signal transduction such as protein
kinase, metabolic enzymes, heat shock proteins (HSP 70, HSP
90), Annexin and Rab family proteins, tetraspanins (CD9, CD63,
CD81), various transmembrane proteins, andmajor histocompat-
ibility complex class I (MHC I) molecules. Particular expression
of some proteins may be present, such as major histocompat-
ibility complex class II (MHC II) on exosomes derived from
antigen-presenting cells such as B-cells or dendritic cells (DCs) or
some tumor antigens such as MelanA/Mart-1 (16, 17). Because of
their endosomal origin, nuclear, mithochondrial, or endoplastic
proteins have not been found in exosomes (13).
In addition to this protein content, exosomes bear molecules
such as lipids, mRNA, and non-coding RNAs, including micro
RNAs (miRNAs) that are delivered and properly translated in
target cells (6, 17). The latter is an important feature because
the presence of mRNA in exosomes results in the transfer of
genetic information allowing protein expression to take place at
a distance.
Overall, all these features have allowed characterization and
isolation of exosomes from other microvesicles secreted by cells
into the extracellular compartment. The classic method to isolate
exosomes, is the differential centrifugation and ultracentrifuga-
tion. However, over the last few years, new methods have been
developed either to obtain large quantities of exosomes to be used
in clinical trials which include, for example, the ultrafiltration
(18, 19) or in an attempt to obtain pure exosomes preparations,
as the use of monoclonal antibodies directed to marker proteins
on the surface of exosomes bound to magnetic beads (20). In
addition, microvesicles have been differentiated and classified
according to various characteristics such as morphology, density,
expression of marker proteins, size and a very important feature:
their intracellular origin.
Until recently, it has generally been accepted that EV differ
in their physiochemical characteristics such as size, density as
determined by their sedimentation equilibration in sucrose gra-
dient, and the expression of main protein markers. Most of the
works that have been done in the field relay on these properties to
developmethods as those mentioned earlier to isolate and charac-
terize the different EV. However, recent works have reported over-
lapping characteristics and functions for the EV. In fact, a single
cell can produce different EV, including exosomes. In this sense,
there is a general concern among scientists working in the field
regarding the representativeness of the current literature data. The
International Society for Extracellular Vesicles has published a
paper proposing standardized methods to isolate EV. Thus, new
methods and more accurate markers are under evaluation (21).
Detailed evidences of the heterogeneity of EV preparations have
recently been reviewed by Colombo et al. (7).
Although the primary role attributed to exosomes has been the
removal of unnecessary proteins from the cells, their principal
function described is their role in cell–cell communication (17).
In addition, they participate in several different functions and in
a large variety of pathways as they are biologically active vesicles
secreted to the extracellular environment (13).
The Role of Exosomes in Immune Function
The role of exosomes in the stimulation of the immune system
has been extensively studied and a recent study in deep review
has been published discussing how exosomes regulates immune
response (6). In this review we will discuss some of the most
relevant findings.
The original work carried out by Raposo et al. demonstrat-
ing the importance of exosomes derived from B-cells in antigen
presentation and T-cell stimulation has changed the idea that
thesemicrovesicles servemerely as a clearance system for obsolete
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proteins (22). Since the publication of this work, numerous studies
have confirmed that exosomes derived from professional antigen
presenting cells, such as DCs, express class I, class II MHC, adhe-
sion, and co-stimulatory molecules. These characteristics enable
these exosomes to activate directly CD8+ and CD4+ T-cells
inducing a strong immunogenic response (2, 4, 23). DCs pulsed
with tumor peptides release immunogenic exosomes and elicit
a strong CD8+ T-cell-dependent anti-tumor immune response
(2). In fact, it has been demonstrated that exosomes can acti-
vate T-cells either by a direct antigen presentation or by an
indirect presentation through transfer of antigenic peptides to
APCs (24–26).
Tumor-derived exosomes express tumor antigens that can acti-
vate DCs, thereby priming the immune system to recognize and
promote a specific cytotoxic response with a higher immuno-
genicity than that accomplished by tumor cell lysates or sol-
uble antigens when used as vaccines (24). Moreover, a single
intraperitoneal injection of tumor peptide-loaded DCs-derived
exosomes can induce a very strong immune response leading
to a delay in tumor growth or to a complete tumor rejection.
This phenomenon is probably because of the high tumor anti-
gen density and also of the presence of HSP with an adjuvant
capacity in the microvesicles, as observed for exosomes derived
from melanoma cells (24, 27–30). In this regard, Lancaster and
Febbraio have determined that exosomes expressing HSP70 can
activate natural killer cells (NKs) andmacrophages (31).This ratio-
nal approach has been probed in several pre-clinical studies and
in Phase I (32, 33) and Phase II clinical trials that are already
under investigation in patients with inoperable non-small cell
lung cancer.
Other immune cells release microvesicles with immune func-
tions, for example, NKs-derived exosomes enclose perforin and
granzyme B and mediate anti-tumor activities either in vitro
or in vivo (34). Furthermore, peptides expressed in exosomes
released by mast cells are presented by DCs and induce specific
immune responses in vivo (35). It has also been reported that
macrophages release IL-1β on inflammasome activation, suggest-
ing a role of these microvesicles in the pro-inflammatory activity
and the innate immune response (36).
Exosomes have also been shown to induce immune suppres-
sion. Over the last yearsmany authors have reported the immuno-
suppressive properties of tumor exosomes which may explain
the low immunogenicity observed in some studies. For example,
tumor exosomes can suppress NK cells by modulating the expres-
sion of the NKG2D receptor (37). These exosomes can promote
the generation of regulatory T-cells (38); induce T-cells apoptosis
through the activation of Fas (39) or tumor necrosis factor ligands
(40) or by the expression of galectin 9 (41) and affect the matura-
tion of DCs (42). The immunosuppressive properties of exosomes
derived from IL-10 treated DCs or DCs genetically modified to
express IL-4 have also been demonstrated in a collagen-induced
arthritis model (43, 44).
Moreover, it has been demonstrated that exosomes derived
from infected cells also display pathogenic antigens that can
induce a specific anti-microbial immune response. For example
exosomes released by endothelial cells infected with Cytomega-
lovirus (45)or Mycobacterium bovis-infected macrophages (46)
can induce a specific immune response. Besides, DCs pulsed with
Toxoplasma gondii promote anti-parasite immunity in mice (47).
Exosomes in Cancer Disease
It is known that a direct interaction between tumor cells and
their environment is essentially required for cancer progression.
To achieve this cell–cell communication, an efficient information
exchangemust exist, being exosomes of paramount importance to
induce a pro-tumoral microenvironment for carcinogenesis and
regulating the immune response to promote tumor progression
and survival. To accomplish these tasks, exosomes are involved
in multiple mechanisms: exosomes released into the extracel-
lular milieu participate in the remodeling of the extracellular
matrix and promote angiogenesis, thrombosis, and tumor cell
proliferation (48, 49).
Owing to their stability, the specific tissue uptake and their
ability to transfer micro or mRNA and proteins to recipient cells,
exosomes may travel to distant sites and promote a pro-tumor
environment to harbor metastatic niches (50). As mentioned
earlier, exosomes may additionally exert an immune suppression
profile, thus favoring a tumor escape mechanism to evade the
immune attack.
It has been demonstrated that exosomes can modulate nearby
or distant target cells by direct contact of their surface molecules
to activate intracellular pathways. Alternatively, on internalization
by membrane fusion or endocytosis, exosomes deliver their pro-
tein or RNA content. Many proteins such as mutant KRAS and
MET oncoprotein have been found to be transported by exosomes
and that their uptake was favored by the hypoxic tumor microen-
vironment. Recently, studies have demonstrated that tumor cells
contain different levels of miRNA and also onco-miRNA which
can post-transcriptionally modulate the acceptor cell function
(51). Exosomes obtained fromnormal prostate epithelial cells with
normal levels of miRNA-16, 143, and 205 could inhibit the in vitro
proliferation of a prostate cell line with lower concentrations of
these miRNA (52).
Cytokines and soluble mediators in combination with tumor-
derived exosomes can recruit bone marrow-derived cells to
tumor pre-metastatic tissue where they contribute to modu-
late the permissive microenvironment for tumor establishment.
Recently, Peinado et al. have demonstrated that melanoma exo-
somes containing MET oncoprotein modulate bone marrow-
derived cells to generate a pro-vascular phenotype in the
lung (53).
As the result of the many cellular functions in tumor devel-
opment and dissemination where exosomes take place, these
microvesicles represent novel biomarkers for a non-invasive and
more accurate diagnosis and prognosis of the disease progression.
Exosomes have several properties that make them preferable
over EV for the purpose of therapeutics, including that exosomes
are stable in vivo and in vitro, bioavailable, well distributed in the
organism, cross the blood–brain barrier, are well tolerate and may
regulate gene expression by transferring miRNA and siRNA to
target cells. Overall, these characteristics highlight the importance
not only as ideal vaccines for cancer treatment, as initially consid-
ered, but alsomore important as natural liposomes for the delivery
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of biologics, allowing multiple opportunities for developing new
alternatives for cancer treatment.
Exosomes Associated to the Generation
and Progression of Neurodegenerative
Diseases
Exosomes have been proposed to be novel actors during normal
development and physiology of the nervous system, acting as
cell–cell communicators and playing functional roles not only
during the development but also during the regeneration of nor-
mal neurons. Lachenal et al. have elucidated the role of exo-
somes in the normal physiology of the central nervous system
by demonstrating the secretion of exosomes in culture by com-
pletely differentiated cortical and hippocampal neurons, being
this secretion regulated by the calcium influx and by the gluta-
matergic synaptic activity (54). Furthermore, Frühbeis et al. have
reported a reciprocal cell–cell communication between neurons
and oligodendrocytes mediated by exosomes (55). Oligodendro-
cytes release exosomes in response to neuronal stress signals and
are internalized by neurons via an endocytic pathway to deliver
protective proteins, glycolytic enzymes, mRNA, and miRNA to
axons, exerting neuroprotection (56).
Apart from the function of exosomes in the normal devel-
opment and physiology of the nervous system, the genera-
tion and progression of many neurodegenerative diseases have
been associated with exosome-mediated transport of misfolded
proteins. Moreover, exosomes have been termed The Trojan
horses of Neurodegeneration because of their capability of ship-
ping toxic agents from unhealthy neurons to their own neigh-
boring cells (57). This nickname has then, and not entirely
correctly, associated exosomes to pathological transport mecha-
nisms involved in several kinds of pathways that finally end in
neurodegeneration.
In Parkinson’s disease, for example, α-synuclein mutated pro-
teins form intracellular oligomers (known as Lewy’s bodies) can be
secreted via exosomes to the extracellular milieu and internalized
bynearby cells, thus spreading the disease fromcell–cell within the
brain. In this regard, Danzer et al. have characterized autophagy
as a protective mechanism in cells, considering it the major degra-
dation pathway for α-synuclein oligomers (58). Any deregulation
in neuronal autophagy might promote the aggregation of these
proteins and their secretion by exosome release, thus spreading the
toxic seed and causing neurodegeneration. Mittelbrunn et al. have
proposed that promoting autophagy (i.e., preventing cells from
exosomal release) may become a novel approach in the treatment
of neurodegenerative diseases (59).
Several hallmark protein accumulations have been charac-
terized in other neurodegenerative diseases like Alzheimer’s, in
which tau protein aggregates form filamentous intracellular inclu-
sions that can spread from affected nerve and glial cells to healthy
ones thus functioning also as potential seeds of the disease. Bol-
mont et al. andGötz et al. have shown that extracellularα-amyloid
aggregates can induce tau pathology in transgenic mice and
finally promote neurodegeneration (60, 61). Moreover, exosome-
associated tau and α-amyloid have been described and it has been
proposed that the exosomal surface can act as the seed responsible
of the β-amyloid aggregation after protein conformational modi-
fications (62).
In this regard, β-site APP-cleaving enzyme 1 (BACE 1) is
responsible for the formation of the aggregates as mentioned ear-
lier. Alvarez-Erviti et al. have accomplished the encapsulation of
BACE 1 siRNA in exosomes, observing after their administration
to amurinemodel for Alzheimer’s, a significant decrease in BACE
1 mRNA and β-amyloid levels (63). They have also demonstrated
that exosomes which have the ability to cross the blood–brain
barrier are non-toxic and that they can be perfectly well toler-
ated. These findings imply that the expression of BACE1 lev-
els, controlled by exosome-mediated siRNA delivery, may be an
interesting breakthrough in the treatment of Alzheimer’s disease.
Exosomes were also implicated in the propagation of PrPSc
(the infectious agent associated with prion diseases such as
Creutzfeldt–Jakob disease and Gerstmann–Sträussler–Scheinker
syndrome) (64–66).
In an interesting study it was demonstrated a differential
expression of specific exosomal miRNA in post-mortem brain
samples in patients with Scizophrenia and bipolar disorders (miR-
497 and miR-29c) compared with those from normal control
samples (67).
Owing to the fact that a variety of aggregating proteins
involved in neurodegenerative diseases have a direct association
with exosomes, these nanovesicles have become an interesting
biomarker for diagnostic and prognostic. Moreover, their capabil-
ity to accomplish targeted neuron-to-neuron transport transforms
them in potentially specialized carriers of therapeutic drugs for
neurologic and psychiatric disorders. In addition, exosomesmight
be used for controlling the disease by silencing or restoring the
normal content of miRNA.
The Role of Exosomes in Cardiovascular
Diseases
Cardiovascular diseases are one of the leading causes of death
worldwide. Although patients can control some of the behavioral
risk factors, physiological factors responsible for heart damage are
major goals to be attained.
Several authors have found a direct association between
cardiovascular diseases and high concentrations of circulating
microvesicles. Exosomes have pro-angiogenesis, pro-coagulant
and pro- and/or anti-inflammatory effects as well as an opposing
impact on the vascular tone and vessel wall. These features of exo-
somes are probably because of their capability of transporting and
cell–cell transferring of proteins, mRNAs, and miRNA, among
others (68).
In this regard, exosomes have been proved to reflect stress
conditions by modifying their protein or mRNA concentration
(69). These molecular components associated with exosomes may
play a role in a variety of cellular physiological mechanisms.
Waldenström et al. have extracted total RNA from culture-isolated
cardiomyocyte exosomes (cardiosomes) and have accomplished
the identification of 1520 mRNAs similar to those found in car-
diomyocytes. Moreover, almost one-third of these mRNAs had
a direct relationship with biological mechanisms, including gene
expression changes (70).
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Generally, after myocardial infarction there is an alteration
in circulating miRNAs which may act in cell–cell communi-
cation between cardiac cells and the bone marrow, opening
up the possibility of generating a cardioprotective mechanism
via the paracrine activation of cardioprotective kinase path-
ways (71). Chen et al. have demonstrated that exosomes derived
from cardiac progenitor cells (CPCs) can protect cardiomy-
ocytes from oxidative stress in vitro and in vivo by inhibiting
ischemia/reperfusion-induced apoptosis, finding enrichment in
miR-451 in CPC-derived exosomes when compared with CPC.
The transcription of miR-451 responds to GATA4, a transcrip-
tion factor associated with cardiac morphogenesis, cardiomy-
ocytes survival, and cardiac function maintenance in the adult
heart (72).
On the other hand, it has been proved that exosomes derived
from cultured cells under hypoxia conditions contain fibronectin,
collagen, and lysyl-oxidase-like 2 (LOXL2) in their protein con-
tent, suggesting the participation of these proteins in cytoskeletal
and extracellular matrix rearrangements of neighboring or distant
cells (69).
Moreover, Liao et al. have shown that cardiomyocytes are able
to produce TNF-α after induction via hypoxia-inducible factor
1 (HIF-1). This cytokine is present in exosomes during hypoxic
conditions and has been demonstrated to contribute actively to
inflammation and cardiac remodeling (73).
All these features of exosomes have led Yellon and Davidson
to name these nanovesicles “dark matter of the body” – invisible
to direct microscopy, but whose existence can be inferred by the
effects they have on other cells” (71).
Moreover, their capacity to transport such variety of molecules
may allow exosomes to provide a biological “snapshot” of the cell
physiological conditions (71) which, in turn, reflects the health
status of the individual.
In summary, all these characteristics make exosomes dynamic
vesicles endowed with the ability of transporting a great variety
of molecules and, taking into account the specificity of their
surface proteins, they have been promoted as specific therapeutic
transporters for cardiovascular diseases.
The Role of Exosomes in Pregnancy
To achieve a successful pregnancy, a specific suppression of the
maternal immune system and a homeostatic balance to preserve
an adequate utero-placental circulation are required. During this
process various modulatory signals are released in different forms
including EVs.
Pregnancy is an immunological phenomenon where the semi-
allogeneic fetus is not rejected because of the immune tolerance
induced toward it. In this regard, exosomes with immunosuppres-
sant activities were found to be increased in pregnant women,
compared with non-pregnant ones. Moreover, exosomes isolated
from sera of women with full-term pregnancies are present at
significantly greater concentrations than those from pregnancies
delivering pre-term.
The syncytiotrophoblast of the human placenta continuously
and constitutively produces and secretes exosomes to thematernal
bloodstream. These exosomes exhibit a redundant number of
mechanisms that inhibit the function of the maternal immune
system during pregnancy and promote the survival of the fetus.
These microvesicles express significantly higher levels of the pro-
apoptotic molecules Fas ligand (FasL), TRAIL, and PD-L1, induc-
ing T-cell death. Placenta-derived exosomes which express FasL
also suppress CD3-ζ chain and the enzyme Janus kinase 3 (JAK3),
leading to T-cell anergy. In addition, it has been reported that
placental exosomes also carryNKG2D ligand (the ligandmolecule
for the activating receptor NKG2D express on NK cells) that may
downregulate the activity of NK cells by binding toNKG2D recep-
tor and consequently impairing the maternal cytotoxic activity
(74–76).
It has been reported that exosomes released in a primary
culture of cytotrophoblast cells contain biologically active pro-
teins that can interact with the maternal endothelium and regu-
late their function (e.g., migration and angiogenesis) (77). Fur-
thermore, exosomes isolated from plasmas of pregnant healthy
women in the first trimester promote vascular cell migration
from the uterine spiral arteries and may play a role in regulating
the endothelium response to maternal adaptation to pregnancy.
However, under pathological conditions (e.g., proinflammatory
states and pre-eclampsia), the bioactivity of placental exosomes is
reduced (78).
Placental miRNAs are abundant in the plasma of pregnant
women and are upregulated in pre-eclampsia. It has been pro-
posed that these specific placental miRNA are extracellularly
secreted to the maternal circulation from the syncytiotrophoblast
through exosomes. The diagnostic and prognostic usefulness
of exosomal miRNAs are presently being investigated. How-
ever, little is known about the role of placental exosome-
associated miRNAs in maternal cells and tissues during preg-
nancy (79).
During pregnancy, maternal circulation is characterized for
the presence of different EV simultaneously secreted by the
syncytiotrophoblast, differing in size, morphology, and func-
tion (80). Syncytiotrophoblast-derived exosomes as stated earlier
are immunosuppressive down-regulating maternal immune sys-
tem. Syncytiotrophoblast-derived microvesicles/microparticles
(STBM) are larger EV and may include apoptotic or necrotic
material, the former immunosuppressive and the latter immunos-
timulatory, anti-angiogenic and procoagulant (80). It is suppose
that during normal pregnancy, a delicate balance occurs between
STBM and exosomes, favoring STMB according with a mild sys-
temic inflammation distinctive of normal pregnancy. In contrast,
in pathological condition such as infertility, recurrent abortions,
pre-eclampsia, pre-term labor, and pre-mature birth, this balance
is broken. For example, in pre-eclampsia, inflammatory stress
could activate the syncytiotrophoblast causing it to release STMB
with pro-inflammatory, anti-angiogenic, and procoagulant activ-
ities (80, 81).
Although the role of immunosuppressive placental exosomes
during normal pregnancy is clear, the contribution of exosomes
in pathological pregnancies and related diseases, such as recur-
rent abortions and infertility, need a more profound evaluation.
The knowledge derived in these areas will open up possibilities
for novel, exosome-based treatments of pregnancy failure and
infertility.
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The Role of Exosomes in Infectious
Diseases
Over the last years, it has been well documented that mammalian
cells infected by single-cell eukaryotic/prokaryotic pathogens or
even prions secrete exosomes with different purposes. Besides,
bacteria secrete biological active vesicles named outer membrane
vesicles (OMVs); fungi and eukaryotic parasites also produce EVs
(82). Moreover, it is known that even parasitic trematodes and
nematodes release exosomes as an immunomodulatory mecha-
nism (83). Significantly, these microvesicles were demonstrated to
play an important role in infection biology. Apart from the widely
studied immunomodulatory effects, pathogen-released exosomes
are known to carry specific virulence factors, such as proteins,
mRNA, and miRNA, which contribute to spread the infection. As
a consequence, microvescicles can either expand or contain the
infection being thus beneficial for either the pathogen or the host.
Prions are abnormally folded proteins with the ability to prop-
agate in the central nervous system causing fatal neurodegen-
erative disorders. Infectious prion proteins (PrPSc) have been
identified in exosomes derived from the conditioned media of
mammalian neurons (64, 66). These exosomes were internalized
by bystander normal cells, transforming naturally occurring cellu-
lar prion proteins (PrPc) into misfolded infectious prion proteins
(PrPSc), suggesting that exosomes may contribute to intercellular
membrane exchange and dissemination of prions throughout the
organism. Moreover, the intracerebral inoculation of exosomes
obtained from infected cell cultures has proved to cause clini-
cal disease in mice (64, 84). Recently, exosomes inclosing prion
proteins were also isolated from plasma of mice bearing transmis-
sible spongiform encephalopathy, suggesting a possible spread of
transmissible spongiform encephalopathies via the blood (85).
In viral infections, microvescicles, and particularly exosomes,
have been involved in variousmechanisms, depending on the type
of virus, its life cycle, and the type of infected cell.
HIV-1 virus has developed many exosome-mediated strate-
gies to manipulate the host’s cell machinery. For example, exo-
somes take part in the transfer of proteins, and RNA (miRNA,
sRNA) from infected to non-infected cells, transporting these
components even to distant cells. Exosome-mediated transport
and deliver of functional proteins to recipient cells has been
demonstrated in HIV-1 infected macrophages (86). This phe-
nomenon has been demonstrated for crucial proteins for HIV-1
infection such as Gag, p17, and Nef. For example, Nef is incorpo-
rated into exosomes released from infected cells and subsequently
induces apoptosis of uninfected CD4+ T-cells contributing to
viral immune suppression (87). In addition to the proteins, miR-
NAs transported by exosomes have been demonstrated to be
involved in HIV-associated neuronal dysfunction and susceptibil-
ity to viral infection (88). In addition, HIV-1 particles captured
by immature DCs (iDCs) are exocytosed in association with exo-
somes and could mediate trans-infection of CD4+ T-cells (89).
On the other hand, HIV-1 has also developed a strategy known as
The Trojan horse hypothesis of HIV trans-infection (90, 91). This
model proposes that HIV-1 enters mature DC (mDC). The virus
is retained in the MVB compartment and follows the same traf-
ficking pathway used by DC exosomes for antigen dissemination
to amplify antigen presentation during pathogen invasion (16, 91).
Afterwards, mDC release them to trans-infect CD4+ cells, mainly
in the lymph nodes (90–92).
Another retrovirus infection in which exosomes play an impor-
tant role during pathogenic viral infection is the Human T-
lymphotropic virus type 1 (HTLV-1). The extracellular delivery
of functional HTLV-1 proteins as the trans-activator protein Tax,
as well as viral mRNA transcripts including Tax, HBZ, and Env
to uninfected recipient cells via exosomes, protect them from
apoptosis under stress conditions and transfers functional HTLV-
1 molecules to this uninfected recipient cells contributing to the
pathogenesis of HTLV-1 (93).
Recent evidence indicates that Hepatitis B, C, and E viruses
(HBV, HCV, and HEV) also employ the exosomal pathway
machinery to mediate alternative active viral transmission and
disease persistence. Moreover, it has been demonstrated that
exosomes isolated from sera of chronic HCV-infected patients
contain HCV RNA, and these exosomes could mediate viral
receptor-independent transmission of HCV to uninfected hep-
atocytes (94). Furthermore, the exosomal export of viral RNA
may serve both as a viral strategy to evade the immune system
spreading the infection, and as a host’s strategy to induce an innate
response in bystander cells. In this regard, exosomes derived from
HCV-infected cells can also induce the production of type I IFNby
the transference of immunostimulatory viral RNA from infected
cells to DCs and trigger the production of IFN-α (95).
Members of the Herpes virus family, such as Human Her-
pes Virus and Herpes simplex, Epstein–Barr virus and human
Cytomegalovirus, have also been studied for their interaction
with cellular exosomes. As described for retroviruses, the Herpes
virus captures the cellular pathway for exosomes biogenesis and
release. In addition, enhances virus loaded exosomes production,
supporting the persistence and dissemination of viral particles.
Furthermore, exosomes may contribute either to the viral escape
from the immunological surveillance or to interfere with the
transport of antigens to the host’s immune system (96).
Exosomes derived from Epstein–Barr virus-infected cells have
also been involved in MVB biogenesis, viral egress, and infec-
tion to neighboring uninfected cells. In addition, Epstein–Barr
virus-infected B-cells can deliver viral BART miRNA to DCs,
thus leading to the exosomal-dependent immune suppression in
EBV-associated lymphomas (97, 98).
Gram-negative bacteria release OMV to communicate with
prokaryotic and eukaryotic cells. They carry and transmit viru-
lence factors, mediate bacterial binding and invasion, cause cyto-
toxicity, and modulate the host’s immune response (99, 100).
Furthermore, exosomes secreted by human infected host cells play
a relevant role in the bacteria–host interaction. This characteris-
tic is especially significant to identify intracellular pathogens, as
bacterial products are not always readily present in fluids for the
pathogen detection and diagnosis. In this regard, the works done
with Mycoplasma tuberculosis and M. bovis have yielded relevant
results. M. tuberculosis or M. bovis-infected macrophages release
exosomes containing pathogen-derived antigens and these vesi-
cles activate both the innate and acquired immune responses (46,
101, 102) inducing the production of pro-inflammatory cytokines
by naïve cells. Exosomes expressingmycobacterial molecules have
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been detected in the serum of patients with acute and latent tuber-
culosis infection. These findings not only enabled the diagnosis
but also served as active or latent phase markers of the disease
(103).
The expression of specific bacterial proteins either on OM or
on exosomes derived from infected as well as from DCs pulsed
with microorganism peptides opened up a new alternative for
the development of prophylactic or therapeutic bacterial cell-free
vaccines.
Finally, exosomes from the fungus Cryptococcus neoformans
and from parasites such as Trichomonas vaginalis, Trypanosoma
cruzi, Leishmania spp., Plasmodium falciparum, Toxoplasma
gondii (104), and helminthes (83) have also been described. These
vesicles express virulence factors and, in addition, stimulate both
pro-and anti-inflammatory responses in host cells (104). Interest-
ingly, Regev-Rudzki et al. have reported P. falciparum within red
blood cells directly communicate to the parasites population using
exosome-like vesicles that are capable of delivering genes (105),
inducing the promotion and differentiation to sexual form of the
parasite.
As stated earlier, the exosomes secreted in response to an infec-
tion are implicated in many processes of the infection biology.
The exosomes isolated from infected cells may be regulated to
eliminate or to attenuate virulence factors to control the spreading
of the infection. As they modulate the immune response, exo-
somes derived from the host’s cell or from pathogens could be
novel candidates for the design of acellular vaccines. In addition,
exosomes can also be employed as infection biomarkers.
Diagnosis and Potential Clinical
Application of Exosomes
The aim of this review was to discuss some significant aspects of
exosomes. First, exosomes may be isolated from almost every cell,
not only from eukaryotic but also from prokaryotic cells. Second,
microvesicles participate in the regulation of central normal bio-
logical processes such as the immune response, pregnancy, tissue
repair, and blood coagulation, among others. Third, exosomes
are involved in pathobiological mechanisms related to the most
frequent types of diseases affecting the population such as neu-
rodegenerative disorders, tumorigenesis, and infectious diseases.
Fourth, these microvesicles may be captured specifically by cells
where they can deliver their content, and finally, they are very
stable both in vivo (in systemic circulation) and in vitro (they can
be preserved frozen for a long period of time without losing their
biological properties) (15).
Given the importance of exosomes in normal and pathobiolog-
ical conditions, microvesicles are being studied for their potential
therapeutic uses. For example, they are evaluated as biomarkers
for the diagnosis and disease follow-up, as immunomodulators
to suppress or stimulate the immune system, as vectors for drug
delivery, and as therapeutic agents per se (Figure 1).
One of the hallmark properties of exosomes is the expression of
specific proteins ormiRNA belonging to the cells fromwhich they
derive. In addition, theymay be isolated from fluids such as blood,
urine, saliva, amniotic fluid, malignant ascites, bronchoalveolar
lavage fluid, synovial fluid, and breast milk. These characteristics
were the starting point of many of studies aiming at proving
exosomes as potential biomarkers for the diagnosis and prognosis
of diseases.
Nowadays, cancer diagnostics rely on biopsies. The poten-
tial uses of exosomes have the advantage of being a sensitive
and non-invasive method, allowing the detection of tumors at
an early stage. Cancer exosomes have been found to be useful
for the detection of many types of tumors: prostate, breast, and
ovarian cancer; glioblastoma and melanoma, among others (106–
110). As mentioned earlier, exosomes transport misfolded pro-
teins associated to neurodegenerative disorders. In Alzheimer’s
disease, the detection of α-amyloid 42 and tau proteins was
possible in cerebrospinal fluid samples at an early stage of the
disease, thus opening up the possibility of an early detection (111,
112). A number of works have described the association of exo-
somes isolated from urine with several kidney pathologies such
as renal ischemia/reperfusion, nephrotic syndrome, and acute
kidney injury (113–115). The levels of circulating placental exo-
somes expressing immunosuppressivemolecules (FasL) are under
investigation to be used as a biomarker to detect complicated
pregnancies (75).
Finally, exosomes proved to be a good marker for the diag-
nosis of infectious diseases. Infectious RNA and proteins are
expressed on exosomes, including viral and misfolded pro-
teins allowing the development of sensitive tests, not only to
detect the causative agent but also to followup the infection.
In this regard, exosomes are especially useful to detect active
and latent forms of intracellular infections, such as tubercu-
losis. In a recent study, 33 unique proteins of Mycobacterium
tuberculosis were identified from exosomes isolated from human
serum that may serve as biomarkers for persistent active and
latent tuberculosis (103). Exosomes from human serum are also
employed to detect HIV-positive patients and this test is at present
commercialized (116).
Another field of intensive study is the use of exosomes to
modulate the immune system. Because the pioneer works of
Raposo et al. demonstrated that exosomes derived from antigen-
presenting cells (B-cells and DCs) contained both MHC I and
MHC II molecules and that they could elicit a specific anti-
tumoral immune response (22), a myriad of studies employing
exosomes as acellular vaccines have been published not only for
cancer but also for infectious diseases. As already stated, numer-
ous Phase I protocols have been conducted in cancer patients
using an exosomal vaccination. Among them are the vaccination
ofmetastaticmelanoma patients (5), advanced non-small cell lung
cancer with autologous DC-derived exosomes (117), and patients
with colorectal cancer immunized with tumor exosomes derived
from ascitic fluid (118).
Following the same strategy, protocols employing DCs pulsed
with peptides obtained from infectious agents were developed.
For instance, DC pulsed with diphtheria toxin (119), or with
Streptococcus pneumoniae capsular polysaccharide Cps14 (120),
for bacterial diseases and with sonicates from tachyzoites of Toxo-
plasma gondii (47) were investigated.
As immunomodulators, exosomes may be either immunoacti-
vating or immunosuppressive agents. Exosomes were proposed as
acellular antigens for the development of vaccines against either
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FIGURE 1 | Role of exosomes in different tissues and their potential use in human diseases.
infectious diseases or tumors. For example, immunization with
exosomes derived from reticulocytes infected with a Plasmodium
yoelli elicits protective immune responses. This strategy offers a
novel platform to develop a vaccine against malaria infection to
induce full- and long-lasting protection on this lethal infection
(121). Cancer vaccines employing unmodified exosomes (24, 122)
or exosomes engineering to express particular molecules derived
from tumor cells such as IL-18 or HSP (123–125) induced specific
anti-tumor immunity. Using immunosuppressive exosomes from
iDCs, it has been possible to induce a donor-specific suppression
in a mismatched cardiac allograft model (126, 127). EVs derived
from genetically modified DCs expressing FasL, IL-10, or IL-4
successfully suppressed delayed-type hypersensitivity in a model
of collagen-induced arthritis (43, 44, 128, 129).
Exosomes are also important therapeutic agents per se. EV
derived from mesenchymal stem cells have the ability to induce
tissue regeneration by delivering growth factors, proteins,miRNA,
mRNA non-coding RNA, and lipids. Several reports have demon-
strated the feasibility to regenerate cardiac tissue and neo-
vascularization in models of myocardial infarction and kid-
ney injury using exosomes from steam cells (MSC-exo) and
endothelial progenitor cells (130). A recent paper by Korde-
las et al. (131) has reported a successful therapy for refrac-
tory graft-versus-host disease (GvHD) employing MSC-exo in
a pediatric patient. In this regard, MSC-exo are under approval
for pediatric GvHD treatment in Canada and New Zealand
(132). In remarkable studies, it has been demonstrated that sys-
temic administration of MSC-exo effectively improved functional
recovery in rats and after stroke (133), and after traumatic brain
injury (134) by increasing neurite remodeling, neurogenesis, and
angiogenesis.
Owing to their natural origin, exosomes constitute an efficient
tissue-specific, non-immunogenic carrier to deliver therapeutic
drugs. The fact that exosomes can be engineered to express foreign
proteins, miRNA and also siRNA, allows not only the expression
of proteins in a tissue-specific manner, but also the silencing of
specific genes. For instance, exosomes effectively delivered siRNA
can knockout genes inside tumor target cells in vitro (135) and
in vivo into neuronal cells by intravenous injection of themodified
vesicles (63). Similarly, mRNAwas efficiently incorporated to and
expressed in tumor cells (136). These approaches illustrate the
possibility to use human exosomes as vectors in RNA-based gene
therapy for neurodegenerative disorders, cancer as well as for the
treatment of other pathologies.
As the potential therapeutic application of exosomes has gained
considerable interest, an important point is starting to be con-
sidered. It refers to the kinetics, biodistribution, and clearance
of exosomes on systemic administration. Recent studies alert
about the rapid clearance of exosomes by the liver and spleen
(137–139). In a recent work by Smyth et al., they observed
a rapid clearance and minimal tumor accumulation of intra-
venously injected tumor exosomes, limiting their employment
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as drug delivery vehicle. However, a significant greater concen-
tration of the same exosomes were retained in the tumor when
delivered intratumorally (137). To overcome these problems Rana
et al. demonstrated that exosomes may be selectively taken up
by target cell by altering the expression of different tetraspanin
proteins (140).
Further studies are needed to overcome these challenges and
to establish if exosomes could be utilized effectively for drug
delivery.
Concluding Remarks
The interest in exosomes is mainly because of the important bio-
logical and pathobiological functions in which they are involved.
In addition, they offer multiple new therapeutic possibilities
because of their properties that are used to detect and to ameliorate
or cure severe diseases.
Regardless the potential benefits to employ exosomes for
therapeutics that were described, some issues such as the purity
of the exosomes preparation, the co-expression of different
molecules within the microvesicle (proteins and RNAs that may
interfere in the biological function required), and the administra-
tion route to achieve the targeted delivery and the desired effect
remain to be solved. Future research will improve the methods
for isolation of pure exosomes necessary to distinguish them from
other types of microvesicles and to understand the mechanism in
which they are involved. These achievements will help bolster the
early diagnosis, control, prevention and therapy.
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